Stocks Health care SNY

NASDAQ · Health care

Sanofi (SNY)

At December 31, 2025 it held €7.7B in cash against €18.7B of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on February 17, 2026.

Watch SNY in 60 seconds

What Sanofi does

Sanofi is a healthcare company that researches, develops, and manufactures prescription medicines and vaccines. Its products treat conditions in immunology, rare diseases, oncology, cardiovascular disease, and diabetes. The company sells its pharmaceutical products globally to hospitals, pharmacies, and healthcare providers. Its shares trade on NASDAQ under the ticker SNY.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in EUR.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Sanofi has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 17, 2026
   Foreign issuer update 6-K
2. August 25, 2026
   Form N-PX filing N-PX
3. August 6, 2026
   Foreign issuer update 6-K
4. July 30, 2026
   Foreign issuer update 6-K
5. July 30, 2026
   Foreign issuer update 6-K
6. July 28, 2026
   Form 13F-HR filing 13F-HR
7. July 27, 2026
   Foreign issuer update 6-K
8. July 22, 2026
   Passive stake changed SCHEDULE 13G/A
9. July 17, 2026
   Foreign issuer update 6-K
10. July 7, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 7, the latest on August 4, 2026. Insider transactions on SEC

Insider trades

What the people running Sanofi did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns SNY

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about SNY

What does Sanofi do?

Sanofi is a healthcare company that researches, develops, and manufactures prescription medicines and vaccines. Its products treat conditions in immunology, rare diseases, oncology, cardiovascular disease, and diabetes. The company sells its pharmaceutical products globally to hospitals, pharmacies, and healthcare providers. Its shares trade on NASDAQ under the ticker SNY.

Is Sanofi profitable?

Yes. In fiscal 2025 it reported net income of €7.8B.

When did Sanofi last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on February 17, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 17, 2026.

Similar companies

Compare SNY with

Compare SNY with any company

Follow SNY

Get an email when Sanofi files with the SEC: results, executive changes, material agreements and annual reports.

Follow SNY: get an email when it files

Where the numbers come from

Financial figures are the values Sanofi tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.